Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

07/06/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

 

ASH 2018: ECHELON-2 trial

11/12/2018

Prof. Lorenz Trümper about the ECHELON-2 trial.

  • 00:05:21
 

Quarterly Focus on Hematology | CLL

10/01/2019

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

 

ASH 2018: Highlights

11/12/2018

Prof. Anas Younes summarizes some of his highlights of ASH 2018.

  • 00:05:24

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Meet the author 10/01/2019

Quarterly Focus on Hematology | CLL

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

Congress news 30/09/2019

iwCLL 2019 Highlight: future treatment of CLL

Prof. Anna Schuh, MD, hematologist at the University of Oxford (UK), talks about future management of CLL.  David Maloney, MD, PhD, hematologist at the Fred Hutchinson Cancer Research Center in Seattle (USA), talks about CAR-T cell therapy in CLL. 

Congress news 30/09/2019

iwCLL 2019 Highlight: frontline treatment

What are the recommendations for frontline treatment of CLL?  Valentin Goede, MD, hematologist at St. Marien-Hospital in Cologne (Germany), discusses frontline treatment in young and older CLL patients. Prof. Paolo Ghia, MD, medical oncologist at Vita-Salute San Raffaele University in Milan (Italy), catches up on the use of biomarkers to choose the right treatment. Prof. Dominique Bron, MD, hematologist at Jules Bordet Institute in Brussels (Belgium), gives her vision on how to make a choice in frontline CLL treatment. 

Congress news 26/09/2019

iwCLL 2019 Highlight: relapse treatment

What are the recommendations for treatment of relapsed CLL patients?  Prof. John Seymour, MD, hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, talks about BCL2-inhibitors and MRD in relapsed/refractory disease.  Talha Munir, MD, PhD, hematologist at St James’s Hospital in Leeds (UK), explains about the role of MRD in determining the duration of therapy.

Congress news 25/09/2019

iwCLL 2019 Highlight: diagnostic tests

What is the latest news in the field of diagnostic testing at CLL? Prof. Richard Rosenquist, MD, hematologist at the Karolinska University Hospital in Stockholm (Sweden), explains the molecular characterization of CLL.  Andy Rawstron, MD, PhD, clinical researcher at the St. James Institute of Oncology in Leeds (UK), talks about diagnostic tests for CLL, including MRD as an end point. 

Congress news 20/09/2019

ISTH 2019: Highlight Ziekte van von Willebrand

Dr. Sarah O’Brien licht toe hoe de ziekte van von Willebrand zich bij kinderen en jonge vrouwen presenteert, en gaat in op de uitdagingen bij deze patiënten. Promovenda Laura Bukkems werkt aan een model waarmee de von Willebrand factor en factor VIII behoefte rondom een operatie kan worden berekend.

Congress news 20/09/2019

ISTH 2019: Highlight Milde hemofilie

Prof. dr. Karin Fijn van Draat praat u samen met haar promovendi Amal Abdi en Fabienne Kloosterman bij over de morbiditeit en behandeling van milde hemofilie en het risico op remmervorming. En terwijl de meeste onderzoeken naar de gevolgen van hemofilie zich richten op gewrichtsbloedingen, heeft promovenda Anne-Fleur Zwagemaker de incidentie van hersenbloedingen uiteengezet en een aantal risicogroepen geïdentificeerd.

Congress news 20/09/2019

ISTH 2019: Highlight Bispecifieke antilichamen

Wat is de invloed van emicizumab op laboratorische tests? En als deze niet bruikbaar zijn, welke alternatieven hebben we dan? Dit zijn enkele van de vragen waar Steve Kitchen antwoord op geeft. Dr. Elena Santagostina heeft in navolging van de HAVEN 1 tot en met 4 studies gekeken in hoeverre emicizumab in staat is bloedingen tijdens en na operaties te voorkomen en of er behoefte was aan aanvullende factor VIII toediening. Dr. Midori Shima bespreekt zijn ervaring met emicizumab. Wat is er bekend over effectiviteit en tolerabiliteit en welke knelpunten moeten er nog worden overwonnen?

Congress news 10/09/2019

Highlights from the iwCLL 2019 in Edinburgh

The 18th International Workshop on CLL (iwCLL) will take place in Auld Reekie - as Edinburgh used to be called by the Scots - from 20 to 23 September. Are you unable to attend this congress? No worries, MEDtalks will travel to this historic city to bring you the most important news about chronic lymphocytic leukemia (CLL). What news is told about diagnostic tests on CLL? And what are the recommendations for the treatment of patients in the frontline and later lines? Renowned hematologists/researchers will talk about this and more in a series of interviews that can be viewed on our website from the beginning of October. Interviews Diagnostic tests Prof. Richard Rosenquist, MD - hematologist, Karolinska University Hospital, Stockholm, Sweden.  Andy Rawstron, MD, PhD - clinical researcher, St. James Institute of Oncology, Leeds, UK.  CLL immunogenetics and B-cell receptor stereotypes Dr. Kostas Stamatopoulos - physician-scientist, Institute of Applied Forest Sciences CERTH, Thessaloniki, Greece.   The role of NOTCH1 and Richter’s transformation Silvia Deaglio, MD, PhD - oncologist, University of Turin, Italy.  Frontline treatment What are the recommendations for frontline treatment of CLL?  Valentin Goede, MD, hematologist at St. Marien-Hospital in Cologne (Germany), discusses frontline treatment in young and older CLL patients. Prof. Paolo Ghia, MD, medical oncologist at Vita-Salute San Raffaele University in Milan (Italy), catches up on the use of biomarkers to choose the right treatment. Prof. Dominique Bron, MD, hematologist at Jules Bordet Institute in Brussels (Belgium), gives her vision on how to make a choice in frontline CLL treatment.  Relapse treatment Prof. John Seymour, MD - hematologist, Peter MacCallum Cancer Centre, Melbourne, Australia.  Talha Munir, MD, PhD - hematologist, St James’s Hospital, Leeds, UK.   Future treatment of CLL Prof. Anna Schuh, MD, hematologist at the University of Oxford (UK), talks about future management of CLL.  David Maloney, MD, PhD, hematologist at the Fred Hutchinson Cancer Research Center in Seattle (USA), talks about CAR-t cell therapy in CLL.  By registering you gain access to the interviews.

Congress news 04/09/2019

ISTH 2019: Highlight Kanker-geassocieerde trombose

In deze highlight bespreken prof. Marc Carrier en prof. dr. Agnes Lee de mogelijkheden en uitdagingen in de behandeling van kanker-geassocieerde trombose. Eén van die uitdagingen, namelijk verhoogd bloedingsrisico bij zowel kanker als antistolling, wordt nader uitgediept door dr. Erik Klok.